Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Other Financing Activities
Financing cash flows not reported separately.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Other Financing Activities · Q3 FY2026 · quarter ended Sep 2026
Other financing activities growth accelerates
Q3 FY2026 other financing activities of $493K (cash outflow) rose 848.1% year over year, ahead of the +390.1% change in trailing-twelve-month other financing activities.
Context
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +848.1% holds above the trailing-twelve-month pace of +390.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (2.09M) USD
- Year-over-year change
- -189.8%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.09M) | -189.8% |
| FY2024 | 2024-12-31 | 2.33M | +733.3% |
| FY2023 | 2023-12-31 | 279K | -69.1% |
| FY2022 | 2022-12-31 | 904K | -65.7% |
| FY2021 | 2021-12-31 | 2.64M | — |
Other Financing Activities vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 other financing activities of $9.56M is the 7th largest of the 10 companies compared; the peer median is $210K.
- Its year-over-year change of +390.1% is the 3rd highest of 7, against a peer median of -76.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $837.33M | +9646807.9% | — | — | |
| LTM Jun 2026 | $199.96M | — | — | 5548.3% | |
| LTM Sep 2026 | $140.1M | — | — | 3.8% | |
| LTM Jun 2026 | $25.78M | -213.6% | +59.8% | 3.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $19.65M | +476.3% | — | — |
| LTM Jun 2026 | $18.58M | -31.6% | +7.5% | 2.2% | |
| LTM Sep 2026 | $9.56M | +390.1% | — | — | |
| LTM Dec 2025 | $1.86M | -121.8% | +56.4% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $210K | -174.2% | — | 1.1% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PRAX) | $210K | -76.7% | +56.4% | 2.8% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| Deferred Income Tax | 2.09M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.69M | 28.59M | 24.86M | 41.36M | 33.94M |
| Change in Working Capital | 16.13M | (1.78M) | (13.03M) | 10.92M | 22.68M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.27M | 3.89M | (8.86M) | 6.71M | 12.1M |
| Other Working Capital | 8.87M | (5.67M) | (4.17M) | 4.21M | 10.58M |
| Other Non-Cash Items | 1.41M | 1.76M | (121K) | (1.58M) | (2.56M) |
| Operating Cash Flow | (124.55M) | (185.04M) | (111.14M) | (131.76M) | (249.07M) |
| Capital Expenditures | (1.05M) | (444K) | (50K) | 0 | (56K) |
| Acquisitions (Net) | 139.47M | (97.33M) | 0 | 0 | 0 |
| Purchases of Investments | (164.17M) | (83.02M) | 0 | (371.52M) | (623.81M) |
| Sales of Investments | 24.7M | 180.36M | 39M | 123.03M | 312.72M |
| Other Investing Activities | (139.47M) | 97.33M | 0 | 0 | 0 |
| Investing Cash Flow | (140.52M) | 96.89M | 38.95M | (248.49M) | (311.15M) |
| Debt Repayment | (763K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 105.71M | 9.56M | 91.59M | 512M | 704.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.64M | 904K | 279K | 2.33M | (2.09M) |
| Financing Cash Flow | 107.59M | 10.47M | 91.87M | 514.32M | 702.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (157.49M) | (77.69M) | 19.69M | 134.07M | 141.96M |
| Free Cash Flow | (125.6M) | (185.49M) | (111.19M) | (131.76M) | (249.12M) |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.